Kissing Is Not a Gluten Delivery System 

Turns out the internet's advice about carrying a travel toothbrush kit for a celiac partner after meals is... probably overkill.

Researchers at Columbia's Celiac Disease Center ran a genuinely novel prospective study: 10 couples (one partner with biopsy-confirmed celiac, one without) where the non-celiac partner ate 10 saltine crackers — 590 mg of gluten — then kissed their partner for a full minute, tongue and all. Saliva from the celiac partner was tested immediately after. In 90% of exposures, gluten came in under 20 ppm, which is the regulatory threshold for "gluten-free." The two samples that exceeded it (41 and 154 ppm) still represented, at most, 1.5 mg of absorbed gluten — well below the roughly 10 mg/day threshold thought to cause mucosal damage.

The sneaky part: drinking just 4 oz of water before kissing dropped every single sample below 20 ppm, with 60% falling below the level of detection entirely. Meanwhile, water had essentially no effect on gluten concentration in the non-celiac partner's own saliva — suggesting the mechanism is dilution during transfer, not clearance from the source.

Why some participants transferred more remains unclear; chewing patterns and dental anatomy may play a role.

For patients hypervigilant about physical intimacy — and prior research found 39% hesitant to kiss their partner — this gives clinicians something concrete and reassuring to offer.

Lee AR et al., Gastroenterology, April 2026

One Receptor, Different Results: The Genetics Behind GLP-1 Variability

Turns out the reason one patient drops 40 pounds on semaglutide while another barely budges might have something to do with a single variant in the drug’s own receptor.

In a GWAS of nearly 28,000 GLP-1 users, researchers identified a missense variant in GLP1R (rs10305420, p.Pro7Leu) associated with greater weight loss — about 0.76 kg per allele copy. The variant is common in Europeans (roughly 40%) and much less so in African ancestry groups (roughly 7%), and the signal held up in an independent All of Us replication cohort.

Here’s where it gets interesting: the same genomic region also tracks with nausea and vomiting. Co-localization analysis suggests the efficacy and side-effect signals may stem from the same underlying biology — hinting that the patients who respond more strongly could also be more prone to feeling it.

For tirzepatide, there’s another layer. A separate GIPR missense variant (rs1800437, p.Glu354Gln) was associated with higher odds of vomiting — potentially tied to reduced GIP signaling, which may normally help buffer GLP-1–related nausea.

The mechanism is still being worked out, but the broader takeaway is clear: variation in drug-target genes shapes both benefit and tolerability. Genetics isn’t destiny here — it explains only a modest share of response — but it’s one of the clearest signals yet that GLP-1 outcomes aren’t one-size-fits-all.

Su et al., Nature, April 2026

Viagra Might Be a Brain Disease Drug

Sildenafil — yes, that sildenafil — just extended the lifespan of mice and pigs with Leigh syndrome, a fatal mitochondrial disease that currently has zero approved treatments.

Researchers screened 5,632 repurposable compounds in patient-derived neural stem cells, looking for anything that could correct a measurable cellular defect (mitochondrial membrane potential, for the curious). PDE5 inhibitors kept floating to the top. The team prioritized sildenafil for its established pediatric safety profile — it's already used in kids with pulmonary arterial hypertension — then watched it normalize calcium dysregulation, restore neurite outgrowth, and partially reverse a neurodevelopmental gene signature in both 2D and 3D brain organoid models.

The genuinely surprising part: six Leigh syndrome patients treated off-label showed measurable clinical improvements — better motor function, fewer metabolic crises — with disease severity scores either dropping or plateauing against a natural history that typically trends sharply upward.

The mechanism isn't fully pinned down, but the leading thread runs through PRKG1, a downstream target of the cGMP pathway that sildenafil activates. PRKG1 was consistently reduced in patient cells and animal models, and its knockdown alone was enough to reproduce the neuronal branching defects seen in disease.

The 6 patient cohort is tiny and uncontrolled — this needs a randomized trial. But for clinicians managing mitochondrial disease, sildenafil's safety data in children may make it worth watching closely.

Zink et al., Cell, March 2026

Boric Acid Wasn't the Problem After All

Turns out the preservative that's been sitting in urine collection tubes for 50+ years isn't messing with one of the most promising rapid AST methods out there.

Researchers tested rapid microcapillary direct-from-urine (RMD) AST — a "dip-and-test" technology that skips overnight culture — on 352 real diagnostic urine samples, all collected in standard boric acid containers. Against broth microdilution as the reference standard, RMD AST hit 96.95% categorical agreement across seven first-line antibiotics (ampicillin, trimethoprim, ciprofloxacin, nitrofurantoin, and others). Mean time to result: 5.85 hours. Same day.

Here's the sneaky part: boric acid should theoretically interfere with direct growth-based AST — that's been an open question and a practical concern blocking wider adoption. So the team split 90 fresh samples into duplicates, one with boric acid added, one without. Agreement between the pairs? 158/160 (98.75%).

The mechanism is straightforward — serial dilution of the urine into broth before testing appears sufficient to neutralize the bacteriostatic effect, no centrifugation or filtration required.

Limitations stand: single site, small Gram-positive numbers, low resistance prevalence for some antibiotics. But for labs fielding hundreds of boric acid urines daily, the compatibility question now has a real answer.

Needs et al., JAC-Antimicrobial Resistance, April 2026

The clinical literature. Applied to the patients in your waiting room.